Fermented soy permeate reduces cytokine level and oxidative stress in streptozotocin-induced diabetic rats

J Med Food. 2015 Jan;18(1):67-75. doi: 10.1089/jmf.2013.0132.

Abstract

Oxidative stress and inflammation are involved in the development of type 1 diabetes and its complications. Because two compounds found in soy, that is, isoflavones and alpha-galactooligosaccharides, have been shown to exert antioxidant and anti-inflammatory effects, this study aimed to assess the effects of a dietary supplement containing these two active compounds, the fermented soy permeate (FSP). We hypothesized that FSP would be able to reduce in vivo oxidative stress and inflammation in streptozotocin (STZ)-induced type 1 diabetic rats. Thirty male Wistar rats were divided into the control placebo, diabetic placebo, and diabetic FSP-supplemented groups. They received daily, by oral gavage, water (placebo groups) or diluted FSP (0.1 g/day; FSP-supplemented group). After 3 weeks, glycemic regulation (glycemia and fructosamine level); the plasma level of carboxymethyllysine (CML), a marker of systemic oxidative stress in diabetes; and the plasma levels of inflammatory markers (CRP, IL-1β, IL-6, and uric acid) were evaluated. Markers of oxidative damage (isoprostanes and GSH/GSSG), antioxidant enzymatic activity (SOD and GPX), and Mn-SOD content were determined in skeletal muscle (gastrocnemius). Diabetic placebo rats exhibited higher CML levels, lower SOD and GPX activities, and decreased Mn-SOD contents. FSP supplementation in diabetic animals normalized the CML and antioxidant enzymatic activity levels and tended to increase Mn-SOD expression. The markers of inflammation whose levels were increased in the diabetic placebo group were markedly decreased by FSP (IL-1β: -75%, IL-6: -46%, and uric acid: -17%), except for CRP. Our results demonstrate that FSP exhibited antioxidant and anti-inflammatory properties in vivo in STZ-induced diabetic rats.

Keywords: alpha-galactooligosaccharides; inflammation; oxidative stress; rat; soy isoflavones; type 1 diabetes.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / metabolism
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Antioxidants / metabolism
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Biomarkers / blood
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Dietary Supplements
  • Fermentation
  • Galactose / pharmacology
  • Galactose / therapeutic use
  • Glycine max / chemistry*
  • Inflammation / drug therapy
  • Inflammation / etiology
  • Inflammation / metabolism
  • Interleukins / blood*
  • Isoflavones / pharmacology
  • Isoflavones / therapeutic use*
  • Isoprostanes / blood
  • Lysine / analogs & derivatives
  • Lysine / blood
  • Male
  • Oligosaccharides / pharmacology
  • Oligosaccharides / therapeutic use*
  • Oxidative Stress / drug effects*
  • Phytotherapy
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • Rats, Wistar
  • Superoxide Dismutase / metabolism
  • Uric Acid / blood

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Biomarkers
  • Interleukins
  • Isoflavones
  • Isoprostanes
  • Oligosaccharides
  • Plant Extracts
  • Uric Acid
  • N(6)-carboxymethyllysine
  • Superoxide Dismutase
  • Lysine
  • Galactose